Literature DB >> 18046492

Prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis.

Luiz G Darrigo1, Mauro Geller, Aguinaldo Bonalumi Filho, David R Azulay.   

Abstract

OBJECTIVE: To assess prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis and its malignant potential.
METHODS: A retrospective study was conducted through analysis of the database at Centro Nacional de Neurofibromatose [Brazilian Neurofibromatosis Center], collected from the following reference services between 1996 and 2004: Instituto de Dermatologia Prof. Rubem David Azulay da Santa Casa de Misericórdia do Rio de Janeiro, Instituto de Pediatria e Puericultura Martagão Gesteira da Universidade Federal do Rio de Janeiro and Department of Immunology and Microbiology at Faculdade de Medicina de Teresópolis.
RESULTS: Over that period, 104 patients aged between 1-17 years were admitted with clinical diagnosis of type I neurofibromatosis. Of these, 53 were male and 51 were female, and 28 patients (15 male and 13 female) had plexiform neurofibroma (26.9%). Division by age group resulted in 21.42% (six) between 1-5 years; 35.71% (10) between 6-12 years and 42.85% (12) between 13-17 years. Of the 104 patients, two developed a malignant peripheral nerve sheath tumor (1.92%).
CONCLUSIONS: Plexiform neurofibromas are relatively common manifestations in patients with type I neurofibromatosis and may be a cause of significant increase in morbidity and mortality among patients. In this study, we conclude that frequency of plexiform neurofibroma and its malignant potential in the population studied is in agreement with data from the international literature.

Entities:  

Mesh:

Year:  2007        PMID: 18046492     DOI: 10.2223/JPED.1718

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  9 in total

1.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

2.  Moyamoya syndrome associated with neurofibromatosis type 1 in a pediatric patient.

Authors:  Natália Battisti Serafini; Cássio Battisti Serafini; Alanna Santoro Vinhas; Marcio Barbosa Godinho
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

Review 3.  Neurofibromatosis: New Clinical Challenges in the Era of COVID-19.

Authors:  Alessio Ardizzone; Anna Paola Capra; Michela Campolo; Alessia Filippone; Emanuela Esposito; Silvana Briuglia
Journal:  Biomedicines       Date:  2022-04-19

4.  Epidemiological profile and clinical characteristics of 491 Brazilian patients with neurofibromatosis type 1.

Authors:  Luiz Guilherme Darrigo Junior; Victor Evangelista de Faria Ferraz; Marina Candido Visontai Cormedi; Luissa Hikari Hayashi Araujo; Mariana Prado Silva Magalhães; Rafaella Curis Carneiro; Luis Henrique Nunes Sales; Mendel Suchmacher; Karin Soares Cunha; Aguinaldo Bonalumi Filho; David Rubem Azulay; Mauro Geller
Journal:  Brain Behav       Date:  2022-05-04       Impact factor: 3.405

5.  Pigmented (melanotic) diffuse neurofibroma of the back in neurofibromatosis type 1.

Authors:  Reinhard E Friedrich; Christian Hagel
Journal:  GMS Interdiscip Plast Reconstr Surg DGPW       Date:  2018-08-03

6.  Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966.

Authors:  Christina Bergqvist; Amandine Servy; Laurence Valeyrie-Allanore; Salah Ferkal; Patrick Combemale; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2020-02-03       Impact factor: 4.123

7.  Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports.

Authors:  Christos Kosmas; George Tsakonas; Katerina Evgenidi; Argyris Gassiamis; Lefkothea Savva; Nikolaos Mylonakis; Athanasios Karabelis
Journal:  Cases J       Date:  2009-06-09

8.  Awake airtraq intubation in plexiform neurofibroma of face: A new experience.

Authors:  Qazi Ehsan Ali; Syed H Amir; Muzammil Shafi; Tariq R Chaudhri
Journal:  Indian J Anaesth       Date:  2013-01

9.  The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  Alice Heaney; Jeanette Wilburn; Matthew Rouse; Shannon Langmead; Jaishri O Blakeley; Susan Huson; Stephen P McKenna
Journal:  Mol Genet Genomic Med       Date:  2020-10-21       Impact factor: 2.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.